Clinical Trials
114 trialsSTELLAR-002
Exelixis
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Peking University First Hospital
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
Corregene Biotechnology Co., Ltd
ELEPHAS-02
Elephas
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
University of Pittsburgh
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen Inc.
TraveraRTGx
Travera Inc
PRESERVE-009
OncoC4, Inc.
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
Regeneron Pharmaceuticals
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
PNeoVCA
Mayo Clinic
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
EMITT-1
Grey Wolf Therapeutics
SIM0610-101
Jiangsu Simcere Pharmaceutical Co., Ltd.
Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
Zhejiang University
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
AbbVie
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
AccSalus Biosciences, Inc.
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
West China Hospital
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Incyte Corporation
Study of INCA 0186 in Subjects With Advanced Solid Tumors
Incyte Corporation
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Exelixis
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
KEYVIBE-005
Merck Sharp & Dohme LLC
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Incyte Corporation
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Incyte Corporation
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
MOIO
UNICANCER
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
AbbVie
Genomic Testing and Resulting Medical Decisions
Arbeitsgemeinschaft medikamentoese Tumortherapie
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Bristol-Myers Squibb
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
ACROPOLI
SOLTI Breast Cancer Research Group